Clinical Case Study: Efficacy of Dupilumab as a Steroid-Sparing Treatment for Refractory Anti-p200 Pemphigoid in a Patient with Multiple Comorbidities

By
Aikaterini Kyriakou
Christos Minas
Antonios Fantakis
Athanasia Tsaousi
Anastasia Tsitlakidou
Parthena Meltzanidou
Anthi-Maria Lazaridi
Alexandra Fleva
Anastasia Giannakou
Elisavet Lazaridou
Aikaterini Patsatsi
September 7, 2026

Frontiers In Immunology

Overview

This case study presents a 49-year-old woman with refractory anti-p200 pemphigoid who experienced significant corticosteroid toxicity. Treatment with dupilumab resulted in improved pruritus and near-complete remission within two months, allowing for substantial corticosteroid tapering.

Background

Anti-p200 pemphigoid is a rare autoimmune blistering disorder with limited management options and significant morbidity associated with prolonged corticosteroid use. The condition often mimics other blistering diseases, complicating diagnosis and treatment.

Data Highlights

No numerical data available in the article.

Key Findings

A 49-year-old woman with refractory anti-p200 pemphigoid was treated with dupilumab after failing high-dose prednisone and dapsone.
Prior corticosteroid treatment led to significant adverse effects, including hypertension and psychological distress.
Dupilumab was initiated as a steroid-sparing option due to the patient's comorbid diverticulitis.
Improvement in pruritus was noted within two weeks of starting dupilumab.
Near-complete remission was achieved by two months, with disease control maintained for six months.
Substantial tapering of corticosteroids was possible without treatment-related adverse events.

Clinical Implications

Dupilumab may provide an effective alternative for managing refractory anti-p200 pemphigoid, especially in patients experiencing corticosteroid-related toxicity. Clinicians should consider dupilumab in similar cases where traditional therapies have failed.

Conclusion

This case demonstrates the potential of dupilumab as a viable treatment option for refractory anti-p200 pemphigoid, particularly in patients with significant comorbidities and corticosteroid-related complications.